Metabolomics study on primary dysmenorrhea patients during the luteal regression stage based on ultra performance liquid chromatography coupled with quadrupole‑time‑of‑flight mass spectrometry.

Primary dysmenorrhea (PD) is a common gynecological disorder which, while not life‑threatening, severely affects the quality of life of women. Most patients with PD suffer ovarian hormone imbalances caused by uterine contraction, which results in dysmenorrhea. PD patients may also suffer from increases in estrogen levels caused by increased levels of prostaglandin synthesis and release during luteal regression and early menstruation. Although PD pathogenesis has been previously reported on, these studies only examined the menstrual period and neglected the importance of the luteal regression stage. Therefore, the present study used urine metabolomics to examine changes in endogenous substances and detect urine biomarkers for PD during luteal regression. Ultra performance liquid chromatography coupled with quadrupole‑time‑of‑flight mass spectrometry was used to create metabolomic profiles for 36 patients with PD and 27 healthy controls. Principal component analysis and partial least squares discriminate analysis were used to investigate the metabolic alterations associated with PD. Ten biomarkers for PD were identified, including ornithine, dihydrocortisol, histidine, citrulline, sphinganine, phytosphingosine, progesterone, 17‑hydroxyprogesterone, androstenedione, and 15‑keto‑prostaglandin F2α. The specificity and sensitivity of these biomarkers was assessed based on the area under the curve of receiver operator characteristic curves, which can be used to distinguish patients with PD from healthy controls. These results provide novel targets for the treatment of PD.

Introduction

Dysmenorrhea is a common gynecological disorder, occurring during adolescence and throughout reproductive maturity (1). There are two categories; primary and secondary dysmenorrhea. Primary dysmenorrhea (PD) accounts for >90% of dysmenorrhea patients and occurs in the absence of other diseases, while secondary dysmenorrhea is caused by a disease of the reproductive organs, such as endometriosis (1). Dysmenorrhea is characterized by spasmodic pain in the hypogastric and lumbar regions between, prior to and during menstruation, with severe patients experiencing fainting (1). According to previous epidemiological studies using multiple survey methods, primary dysmenorrhea occurs in 20–90% of women (2,3). Although primary dysmenorrhea is not life-threatening, the degree of pain severely affects women's quality of life and ability to work normally. Therefore, the study of clinical treatments for primary dysmenorrhea is of great importance. The luteal regression stage, where the corpus luteum degenerates in the absence of pregnancy, is an important period during the menstrual cycle, and hormonal and endocrinal changes during this time affect the occurrence and development of dysmenorrhea (4).

Metabolomics is a discipline that studies the set of metabolites present at a point in time in vivo, and how surroundings, physiology, pathology and genetic mutations influence the makeup of the metabolome (5). Metabolites are closely associated with phenotypic changes and are often the end result of disease-associated endogenous substance perturbations (6). Urine metabolomics is a non-invasive analysis method that is normally used in screening for disease, but has great potential in studies of metabolomics. Ultra performance liquid chromatography coupled with quadrupole-time-of-flight mass spectrometry (UPLC-Q/TOF-MS) is a powerful method of analysis, advantageous due to more faster analyses, shorter time and increased separation efficiency compared with other traditional instruments (7,8). Due to this high throughput, high sensitivity and high accuracy, it is possible to dynamically analyze urine to identify and resolve metabolic differences in endogenous substances in vivo. The results can provide clinical guidance in the study of disease mechanisms.

Previous studies have primarily been concerned with researching menstruation biomarkers (9). To the best of our knowledge, the mechanisms underlying dysmenorrhea during the luteal regression stage have not yet been reported, making research on the luteal regression stage mechanisms of PD urgently required. Therefore, the changes in endogenous substances during the luteal regression stage were studied, using urine metabolomics combined with receiver operator characteristic (ROC) curves to verify biomarkers. Initially, a UPLC-Q/TOF-MS technique was used to generate a metabolomic profile of urine samples from patients with PD, as well as healthy controls. Principal component analysis (PCA) and partial least squares discriminate analysis (PLS-DA) were used to identify metabolite perturbations. Next, the classification performance (specificity and sensitivity) was verified using the area under the curve (AUC) of the ROC curves. The present study aimed to confirm the endogenous metabolites present at the luteal regression stage and seek potential PD biomarkers from among them. The results of this may assist in the clinical treatment of PD.

Materials and methods

Study subjects and design

The present study was reviewed and approved by the Tianjin University of Traditional Chinese Medicine. The samples used in the present study originated from the same volunteers used by Fang et al (9), and so shared demographic and clinical characteristics. The group included 36 patients with clinically diagnosed PD and 27 healthy controls from the Affiliated Hospital of Tianjin University of Chinese Medicine (Tianjin, China) and Tianjin Maternity Hospital (Tianjin, China). Urine was collected from PD patients and healthy controls during the luteal regression stage, and informed consent was obtained from all participants prior to sample collection. Each volunteer provided written answers detailing age, weight, height, personal and family history of menstrual cramps, and dysmenorrhea pain integral. The pain integral was >8 in all patients with PD. The selection criteria for patients with PD were in accordance with the diagnostic criteria established by the People's Republic of China Ministry of Health Pharmaceutical Council (10) and the National Higher School Teaching Materials Obstetrics and Gynecology, Seventh Edition (11).

Collection of urine samples

Urine samples were collected as described previously (9), and collection was consistent with the clinical inclusion criteria (morning urine collected three days prior to menstruation, and the volume of each sample recorded). Following this, each sample was loaded into 10 ml centrifuge tube, and 1% sodium azide was added. The samples were subjected to centrifugation at 765 × g at 4°C for 15 min. The supernatant was stored at −80°C until analysis.

Urine sample preparation

Urine samples and quality control (QC) samples were prepared as previously described (9). QC samples were mixture of urine from PD patients and healthy controls. Urine samples were prepared as follows: Samples were thawed at room temperature and centrifuged at 8,497 × g at 4°C for 10 min. Next, 200 µl liquid supernatant was added to 200 µl pure water. The liquid was subsequently vortexed for 1 min and centrifuged at 14,360 × g at 4°C for 15 min. Finally, all samples were injected into UPLC-Q/TOF mass spectrometer for analysis. QC samples were prepared as follows: 8 samples were selected from each group by random sampling. QC samples were centrifuged at 8,497 × g at 4°C for 10 min. Liquid supernatant (200 µl) was then added to 200 µl pure water, vortexed for 1 min and centrifuged at 14,360 × g at 4°C for 15 min. QC samples were analyzed once every 6 h and used to test instrument stability, ensuring that conditions remained the same throughout the analysis.

UPLC-Q/TOF-MS analysis

The liquid chromatograph used was the Waters ACQUITY UPLC system (Waters Corporation, Milford, MA, USA). Supernatant (5 µl) was injected into ACQUITY UPLC BEH C18 columns (2.1 mm × 100 mm; 1.7 µm; Waters Corporation). The column temperature was set at 45°C and the flow rate was 0.3 ml min-1. The gradient system consisted of mobile phase A (0.1% formic acid in water) and mobile phase B (0.1% formic acid in acetonitrile) as follows: 0–8.5 min, 1–25% B; 8.5-11 min, 25–50% B; 11–13 min, 50–90% B; 13–15 min, 90–99% B; 15–17 min, 99% B; 17–18.5 min, 99–1% B; 18.5-20 min, 1% B (9).

Mass spectrometry was performed on a Waters Micromass QTOF Micro Synapt high definition mass spectrometer (Waters Corporation). Electrospray ionization (ESI) was used in positive mode. Ion source parameters were as follows: Capillary voltage, 3.0 kV; cone voltage, 30 V; nebulizer pressure, 350 psi; nitrogen gas temperature, 325°C; cone gas flow, 50 l/h; desolvation gas flow, 600 l/h; source temperature, 120°C; desolvation temperature, 350°C; 0.1 sec (interval 0.02 sec) collected once spectrum data and scanned at mass range of m/z 50–1,100.

Data processing and multivariate analysis

Data was initially exported using MarkerLynx V4.1 (Waters Corporation) with peak discovery, peak alignment and raw data filtering to determine potential discriminant variables. A data array that included retention time, m/z values and normalized peak area was then obtained. The multivariate data matrix was exported into SIMCA-P 12.0 software (MKS Instruments, Andover, MA, USA) for PCA and PLS-DA analysis. The PCA model is a statistical sample of the principal contradiction reaction and can resolve the main factor multivariate data, as well as reflect the main features. The data space is compressed, and characteristics of multivariate data in a low-dimensional space are expressed through visual effects. The PLS-DA model was fitted following the adaptation of the data. According to the classification pattern recognition model, compounds were chosen depending on whether they have an important contribution. These data further validate the differences in the compounds between PD patients and healthy controls through metabolic differences in the luteal regression stage (12,13). Cross-validation tests were sorted through for verification. Evaluating urine PLS-DA models requires a higher R2Y value, and Q2 values for these parameters typically. R2X, R2Y and Q2 are larger in the present model, and the R2Y and Q2 are closer to 1, demonstrating the accuracy of the model result (14). Variable-importance plots (VIP) values >1 were used to screen potential biomarkers. Unpaired Student's t-tests were used to determine statistically significant differences between biomarkers in patients with PD and healthy controls. P<0.05 was considered to indicate a statistically significant difference.

Resulting candidate biomarkers were selected based on their molecular weights and use of the formula to predict the elemental composition of a compound. The database was then used to retrieve documents and metabolite candidates, and the candidates were finally confirmed using metabolic standards, references and tandem mass spectrometry information, such as the Human Metabolome Database (HMDB; http://www.hmdb.ca/) (15–17) and MassBank (http://www.massbank.jp/). Related metabolites were submitted to a correlation analysis of metabolic pathways associated with metabolic pathway analysis (MetPA) (18) and the Kyoto Encyclopedia of Genes and Genomes (KEGG; http://www.genome.jp/kegg/) (19).

Results

Metabolomic profiling analysis

Urinary metabolic fingerprints of patients with primary dysmenorrhea (T group) and healthy controls (Z group) during the luteal regression stage are displayed in Fig. 1. Several different peak intensities were clearly detected from the typical base peak intensity (BPI), which indicates two sets of data with metabolite differences in Fig. 1.

Figure 1.

Typical base peak intensity chromatogram of urine for primary dysmenorrhea patients (T) and healthy controls (Z) at positive electrospray ionization mode. Differences in metabolites are indicated.

Data were processed using multivariate statistical analysis methods (Fig. 2). In the PCA scatter plot, each point represents a volunteer sample, making it possible to visually discern the differences between the samples. In addition, anomalous samples can be identified and removed (20,21) to improve the accuracy of the model. PLS-DA (Fig. 2A) was used to identify the metabolites that differentiate patients with PD from the healthy controls. The R2Y and Q2 of the PLS-DA model were 0.992 and 0.806, respectively, demonstrating the accuracy of the model. Finally, a VIP value >1 and unpaired Student's t-tests were used to identify metabolites with significant differences as potential biomarkers. Following this, a score plot (S-plot) of the PLS-DA was used to identify potential discriminatory metabolites (Fig. 2B). Metabolites that are distal from the origin and close to the vertical axis of the S-plot are the differentiating metabolites.

Figure 2.

Multivariate statistical analysis. (A) PLS-DA model of ultra performance liquid chromatography coupled with quadrupole-time-of-flight mass spectrometry data between patients with PD and healthy controls in the luteal regression stage in positive mode. (B) S-plot of PLS-DA model between patients with PD and healthy control. PLS-DA, partial least squares discriminate analysis; PD, primary dysmenorrhea.

Identification of biomarkers

PLS-DA analysis VIP values with >1 ion were used to identify candidate biomarkers. Significantly different endogenous compounds during the luteal regression stage were considered to be the differentiating compounds between patients with PD and healthy controls, resulting in the identification of 10 specific biomarkers. Levels of citrulline, ornithine, androstenedione, progesterone, phytosphingosine, dihydrocortisol and 17-hydroprogesterone were significantly decreased in patients with PD compared with healthy controls during the luteal regression stage (P=0.0426, P=0.0071, P=0.0040, P=0.0359, P=0.0360, P=0.0454 and P=0.0235, respectively; Table I) and levels of sphinganine, histidine and 15-keto-prostaglandin F2α were significantly increased in patients with PD compared with healthy controls during the luteal regression stage (P=0.0136, P=0.0107 and P=0.0001, respectively; Table I).

Table I.

Identified metabolites for discrimination between PD patients and healthy controls in urine samples.

	tR (min)	Metabolite	Obsd [M+H]+	Calcd [M+H]+	Error[c] (ppm)	P-value	Formula	Content change[d] (T/Z)	Pathway
1	10.19	Ornithine[a]	133.1017	133.1015	1.50	0.0071	C5H12N2O2	↓	Arginine and proline metabolism
2	0.78	Histidine[a]	156.0781	156.0775	3.85	0.0107	C6H9N3O2	↑	Histidine metabolism
3	0.98	Citrulline[a]	176.1036	176.1038	−1.14	0.0426	C6H13N3O3	↓	Arginine and proline metabolism
4	10.50	Androstenedione[a]	287.1995	287.1991	1.40	0.0040	C19H26O2	↓	Steroid hormone biosynthesis
5	12.82	Sphinganine[b]	302.3108	302.3110	−0.66	0.0136	C18H39NO2	↑	Sphingolipid metabolism
6	10.41	Progesterone[a]	315.2318	315.2314	1.27	0.0359	C21H30O2	↓	Steroid hormone biosynthesis
7	12.30	Phytosphingosine[a]	318.3054	318.3048	1.88	0.0360	C18H39NO3	↓	Sphingolipid metabolism
8	9.69	17-Hydroxyprogesterone[b]	331.2241	331.2239	0.60	0.0235	C21H30O3	↓	Steroid hormone biosynthesis
9	10.25	15-Keto-prostaglandin F2α[b]	353.2293	353.2287	1.70	0.0001	C20H32O5	↑	Arachidonic acid metabolism
10	10.46	Dihydrocortisol[b]	365.2336	365.2330	1.68	0.0454	C21H32O5	↓	Steroid hormone biosynthesis

Confirmed by standard samples.

Identified by MS/MS information.

ppm was the mass difference in ppm of theoretical and measured m/z of the compounds.

The trend content of primary dysmenorrhea and healthy volunteers.

Metabolite m/z values were used to determine the probable molecular formula using the HMDB database (15–17). Of these compounds, 4 were identified using authentic standards and 6 were identified by comparing the fragments based on their molecular ion information and MS/MS data. An example is 17-hydroxyprogesterone, which exhibited an accurate biomarker mass ([M+H]+ at m/z 331.2241) in the mass spectrum. In positive ion mode, the MS/MS contains the fragment ions m/z 195.1 [M+H-C9H12O]+ and m/z 138.0 [M+H-C12H17O2]+. The HMDB database was also used to confirm the results (15–17).

Biomarker verification

To determine the sensitivity and specificity of the 10 biomarkers identified in the luteal regression stage, SPSS 17.0 (SPSS Inc., Chicago, IL, USA) was used to analyze the ROC curves of the biomarkers. The ROC curves were regarded as a potential diagnosis threshold for the test results, and the sensitivity and specificity were calculated and evaluated. Data were plotted as 1-specificity on the × axis and sensitivity on the y axis (Fig. 3). The ROC curve is proximal to the upper left (Fig. 3B, blue line), and the largest point boundary value of the Youden index (22) is the threshold. Therefore, the sensitivity and specificity of the test are greater, and the rates of misdiagnoses and missed diagnoses are relatively low. With regard to the plotted curve and 45° oblique linear contrast, if most of the curve coincides with the independent variable, the value is a poor predictive value for the dependent variable. If the data curves away from the 45° oblique line more than the independent variable, the value is a better predictive value for the dependent variable. In the present study the biomarkers with AUC >0.7 were considered to have an important role in patients with PD. Finally, as demonstrated in (Fig. 3A), the AUC of 6 metabolites was >0.8. Thus, 6 important biomarker candidates were identified. The combination of the 10 biomarkers' AUC at the 95% confidence interval was 0.950, indicating high sensitivity and specificity during the luteal regression stage (Fig. 3B).

Figure 3.

Receiver operating characteristic curve analysis for (A) the 10 biomarkers individually, and (B) the combination of 10 biomarkers during luteal regression.

Metabolic pathways

MetPA (18), which uses a library of metabolic pathways from the KEGG (19), was used for metabolic pathway analyses of potential biomarkers (Fig. 4). The abscissa is the impact of the pathways. Where the pathway impact value calculated from the pathway topology analysis is >0, that pathway is likely associated with PD. It was revealed that steroid hormone biosynthesis, sphingolipid metabolism, arginine and proline metabolism, histidine metabolism and arachidonic acid metabolism were perturbed at the luteal regression stage in patients with PD (Fig. 4). Finally, the disturbed metabolic pathways detected by UPLC-Q/TOF-MS analysis were analyzed (Fig. 5).

Figure 4.

Metabolic pathways of the patients with PD as analyzed by MetPA. (A) Steroid hormone biosynthesis, (B) sphingolipid metabolism, (C) arginine and proline metabolism, (D) histidine metabolism and (E) arachidonic acid metabolism.

Figure 5.

Schematic diagram of the disturbed metabolic pathways detected by ultra performance liquid chromatography coupled with quadrupole-time-of-flight mass spectrometry analysis. Words in red represent the perturbed metabolites of primary dysmenorrhea during luteal regression. Metabolites written in black were not detected but are relevant for all metabolic pathways. The dotted line denotes the five metabolic pathways. The histograms display the increase and decrease in urinary levels.

Discussion

PD is associated with hormonal substance changes in vivo, and fatty acid buildup in cell membrane phospholipids (23,24). The present study surveyed metabolic variations in patients with PD using UPLC-Q/TOF-MS-based metabolomics during the luteal regression stage. A clear metabolic difference was observed between patients with PD and healthy controls, with citrulline, ornithine, androstenedione, progesterone, phytosphingosine, dihydrocortisol and 17-hydroxyprogesterone levels decreased and sphinganine, histidine and 15-keto-prostaglandin F2α levels increased in patients with PD compared with healthy controls during the luteal regression stage.

Figure 5 illustrates the disturbed metabolic pathways that were detected by UPLC-Q/TOF-MS analysis. Phytosphingosine is converted into ceramide and sphingosine 1 phosphate, and ceramide is converted into sphingosine and sphingomyelin. Sphingosine is an important cell membrane component, being a nerve receptor ligand, a signal transduction effect factor and, in addition, involved in the binding of prostaglandin E2 (PGE2) and prostaglandin F2α (PGF2α) to the appropriate receptor during signal transduction processes (25,26). Phospholipids in the cell membrane are converted into arachidonic acid by phospholipase A2. Following this, cyclic oxidase and PGF synthase generate PGF2α. PGF2α has a strong vasoconstrictory effect, and is involved in the contraction of uterine smooth muscle. Furthermore, 15-ketone-prostaglandin F2α is a PGF2α metabolite, and the level of 15-ketone-prostaglandin F2α was increased in patients with PD. This may lead to uterine contractions, resulting in dysmenorrhea during the luteal regression stage. In addition, increased prostaglandin levels may increase peripheral nerve pain perception (27,28).

Progesterone, androstenedione, dihydrocortisol and 17-hydroxyprogesterone are the metabolic products of steroids, which are a class of bioactive compounds derived from cholesterol. Cholesterol is converted into pregnenolone, which is converted into progesterone by mitochondrial enzymes and isomerases. Initially, progesterone uses 17-hydroxylase to form 17-hydroxyprogesterone, and 17-hydroxyprogesterone is converted into androstenedione by carbon chain lyase. Previous studies have demonstrated that PGF2α levels in the uterine muscle layer positively correlate with estradiol levels and negatively correlate with progesterone levels in the uterine vein. Increased estradiol levels accelerate PGF2α synthesis and release, as well as cause uterine blood vessel spasms and thus dysmenorrhea, but progesterone antagonizes this reaction (29). During luteal regression, progesterone levels in patients with PD was significantly lower than in the healthy control, and estradiol levels were increased. It has previously been reported that the level of progesterone decreased in mice when the animal's pain threshold decreased, but no pain was detected when progesterone secretion levels were high (30). In addition, dihydrocortisol is involved in cortisol metabolism, and in vitro experiments have demonstrated that cortisol increases the prostaglandin levels in uterine smooth muscle tissue and increases myometrial contractions (31). The results of the present study also suggest that changes in prostaglandin levels may induce dysmenorrhea during luteal regression.

Histidine is converted to histamine by histamine decarboxylase. Histamine is a metabolite in mast cells and typically exists in an inactive binding state. Mast cells exist in the female reproductive system and are widely distributed in the human uterine muscle layer. Histamine indirectly regulates normal uterine smooth muscle contraction through activation of its receptors (32,33). Previous studies indicate that activation of the histamine receptor increases pain sensitivity in mice (34). An increase in histidine content leads to an increase in histamine content, which increases uterine smooth muscle contractions and resulted in dysmenorrhea (34).

Arginine is the precursor of nitric oxide (NO) and ornithine, which are involved in citrulline synthesis. Nitric oxide is a neurotransmitter involved in modulating peripheral and central pain level, and is important for nervous and immune system regulation. Through the NO-cyclic guanosine monophosphate pathway, NO induces both pain and analgesic effects: When reduced, NO induces pain and results in dysmenorrhea, but when increased it inhibits the induced pain. During luteal regression, ornithine and citrulline are involved in arginine metabolism (35). When ornithine and citrulline levels were reduced, nitric oxide content was reduced and its analgesic effect suppressed, resulting in dysmenorrhea (36). Therefore, in future studies, drug interventions targeting these metabolic pathway biomarkers will be used to alleviate pain, to reduce the distress caused by PD and to discern the optimal time of administration.

By comparing PD biomarkers between menstruation and luteal regression in patients with PD, it was revealed that primary dysmenorrhea patients are affected by perturbations to steroid metabolic pathways during the menstrual period and luteal regression stage (9). The hypothalamus-pituitary-gonadal axis is important for hormone regulation during the menstrual cycle (37). The main ovarian hormones, estrogen and progesterone, regulate menstruation (38). Progesterone is able to promote estradiol transformation into low active estrone, thereby generating reduced prostaglandin, which consequently reduces the extent of uterine smooth muscle contraction and alleviates dysmenorrhea. In the present study, it was observed that the progesterone levels decreased, and also possibly that the prostaglandin levels increased, which were consistent with previous reports (39). Estrogen is able to stimulate PGF2α and vasopressin synthesis, which is released in the uterine spiral artery walls, mediated via PGF2α receptors. PGF2α, in combination with its receptor, leads to the contraction of local blood vessels, and reduced blood flow to the uterus and muscle, due to pain-induced ischemia/hypoxia. Similarly, vasopressin causes the muscle layers of small blood vessels of the uterus to contract, leading to uterine ischemia and pain (27). If a target biomarker is converted to a PD-associated form during luteal regression, and a drug targeting this biomarker is applied during luteal regression, PD may be attenuated. If this occurs, pain in patients with PD may be reduced during menstruation (40). Therefore, discovering these important biomarkers in the luteal regression stage is essential for treating PD.

To conclude, in the present study a UPLC-Q/TOF-MS analysis was used to create metabolic profiles of urine samples during luteal regression, and indicated that metabolomic profiles of patients with PD deviated from the healthy controls. In total, 10 biomarkers were identified in patients with PD during luteal regression, associated with sphingolipid metabolism, steroid hormone biosynthesis and arginine and proline metabolism. ROC curves were used to evaluate biomarker sensitivities and specificities during luteal regression. These results are consistent with the theory of traditional Chinese medicine (TCM) syndrome differentiation, and may help provide novel targets for the treatment of PD.